In the European pharmaceutical industry, there were 18 private equity deals announced in Q3 2023, worth a total value of $1.1bn, according to GlobalData’s Deals Database. The $884.8m acquisition of Ergomed by Permira Advisers in a going private transaction was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes and the Private Equity deal activity are included in GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, private equity deal activity in Europe increased by 189% in Q3 2023 compared with the previous quarter’s total of $380.8m and rose by 31% as compared to Q3 2022. Related deal volume decreased by 33% in Q3 2023 versus the previous quarter and was 33% lower than in Q3 2022.
The top-ranked financial advisors supporting these private equity deals in Europe in Q3 2023 were PricewaterhouseCoopers International; Rothschild & Co; Deloitte NSE with 4, 4, 3 deals respectively.
The top-ranked legal advisors supporting these private equity deals in Europe Q3 2023 were Baker & McKenzie; CMS Legal Services EEIG; Hill Dickinson with 3, 2, 2 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2023 – Thematic Intelligence, buy the report here.